文献速递瓣膜外科心外重症与机械循环支持

左心室辅助装置患者单纯自体主动脉瓣反流的经导管治疗

Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

本研究评估了2017年1月至2023年4月在本中心接受经导管主动脉瓣植入术的27例左心室辅助装置合并临床显著主动脉瓣反流患者的手术结局与生存率。结果显示,使用专用装置或预支架策略可提高手术成功率,住院死亡率为3.7%,中位随访生存388天。

要点

  • 左心室辅助装置合并主动脉瓣反流患者经导管主动脉瓣植入术住院死亡率为3.7%。
  • 使用专用装置或预支架策略均无需第二次经导管心脏瓣膜,手术成功率高。
  • 标准装置组37.5%需第二次经导管心脏瓣膜,术中反流>微量者占12.5%。

核心结论

  • 经导管主动脉瓣植入术在左心室辅助装置合并主动脉瓣反流患者中取得有前景的手术结局和早期生存率,专用装置和预支架技术可提高手术成功率,仍需继续研究以优化这一复杂患者群体的结局。

研究设计与样本

  • 单中心研究,纳入2017年1月至2023年4月在本中心接受择期或紧急经导管主动脉瓣植入术的27例左心室辅助装置合并临床显著主动脉瓣反流患者。

主要发现

  • 14.8%的患者使用主动脉瓣反流专用经导管主动脉瓣植入装置,均无需第二次经导管心脏瓣膜,术中无主动脉瓣反流,出院时1例(25%)有超过微量的主动脉瓣反流。
  • 25.9%的患者使用标准经导管主动脉瓣植入装置行装置着陆区预支架,均无需第二次经导管心脏瓣膜,术中无主动脉瓣反流,出院时无至微量主动脉瓣反流。
  • 59.3%的患者使用标准经导管主动脉瓣植入装置,其中37.5%需要第二次经导管心脏瓣膜,该亚组术中主动脉瓣反流超过微量者占12.5%,出院时降至6.25%。
  • 住院死亡率为3.7%,中位随访生存期为388天(四分位距208-1167天)。

关键数值与推荐

  • 主要终点为手术成功率,即无需第二次经导管心脏瓣膜且无术后主动脉瓣反流/瓣周漏。
  • 次要结局包括生存率和不良事件。

临床怎么用

  • 作者认为,专用经导管主动脉瓣植入装置和预支架技术可提高左心室辅助装置合并主动脉瓣反流患者的手术成功率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Aortic valve regurgitation (AR) frequently complicates the clinical course after left ventricular assist device (LVAD) implantation. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement (SAVR) in this cohort with a mostly high surgical risk profile. The unique challenges in LVAD patients, such as presence of non-calcified aortic valves and annular dilatation, raise concerns about device migration and paravalvular leakage (PVL) leading to missing device success. This study evaluates procedural outcomes and survival rates in LVAD patients who underwent TAVI, emphasizing strategies to enhance device success. METHODS: Between January 2017 and April 2023, 27 LVAD patients with clinically significant AR underwent elective or urgent TAVI at our centre. Primary end-points were procedural success rates, without the need for a second transcatheter heart valve (THV) and postprocedural AR/PVL. Secondary outcomes included survival rates and adverse events. RESULTS: Among the cohort, 14.8% received AR-dedicated TAVI devices, with none requiring a second THV. There was no intraprocedural AR, and 1 patient (25%) had AR > 'trace' at discharge. Additionally, 25.9% underwent device landing zone (DLZ) pre-stenting with a standard TAVI device, all without needing a second THV. There was no intraprocedural AR, and none to trace AR at discharge. Among the 59.3% receiving standard TAVI devices, 37.5% required a second THV. In this subgroup, intraprocedural AR > 'trace' occurred in 12.5%, decreasing to 6.25% at discharge. In-hospital mortality was 3.7%, and median follow-up survival was 388 days (interquartile range 208-1167 days). CONCLUSIONS: TAVI yields promising procedural outcomes and early survival rates in LVAD patients with AR. Tailored TAVI devices and pre-stenting techniques enhance procedural success. Continued research into these strategies is essential to optimize outcomes in this complex patient cohort.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Hinkov H, Lee CB, Pitts L, et al. Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device. Eur J Cardiothorac Surg. 2024. PMID: 38273702. doi:10.1093/ejcts/ezae028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。